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We hypothesized that dynamic perfluorinated gas MRI would sensitively detect mild cystic
fibrosis (CF) lung disease. This cross-sectional study enrolled 20 healthy volunteers and 24
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volume in the first second (FEV1; >80% predicted, n = 9). Dynamic fluorine-19–enhanced
MRI (19F MRI) were acquired during sequential breath holds while breathing
perfluoropropane (PFP) and during gas wash-out. Outcomes included the fraction of lung
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described PFP wash-in and wash-out kinetics. VDP values (mean ± SD) of healthy controls
(3.87% ± 2.7%) were statistically different from moderate CF subjects (19.5% ± 15.5%, P =
0.001) but not from mild CF subjects (10.4% ± 9.9%, P = 0.24). In contrast, the fractional
lung volume with slow gas wash-out was elevated both in subjects with mild (9.61% ±
4.87%; P = 0.0066) and moderate CF (16.01% ± 5.01%; P = 0.0002) when compared with
healthy controls (3.84% ± 2.16%) and distinguished mild from moderate CF (P = 0.006). 19F
MRI detected significant ventilation abnormalities in subjects with CF. The ability of gas
wash-out kinetics to distinguish between healthy and mild CF lung disease subjects makes
19F MRI a potentially valuable method for the characterization of early lung disease in CF.
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Introduction
In the era of highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy, 
new outcome measures that accurately reflect treatment effects and sensitively detect mild CF lung disease are 
needed. Typical clinical trial endpoints (e.g., spirometry, exacerbation frequency) require large sample sizes and 
have limited utility in young and mildly affected patients. Lung clearance index (LCI) is increasingly used in 
pediatric studies, but it is time consuming and difficult to perform in subjects with more advanced lung disease. 
Furthermore, these global lung assessments can be insensitive to regional changes in airflow obstruction, inflam-
mation, and bronchiectasis (1). In contrast, high-resolution CT is able to detect focal disease (2) but requires 
radiation exposure and provides little physiologically relevant functional information outside of gas trapping.
MRI is rapidly emerging as an imaging modality that can detect both structural and functional changes 
within the lung without radiation exposure (3–7). This capability is particularly useful in CF, where bronchi-
ectasis may be quite focal, especially early in the disease process. Recent advances in MR technology, includ-
ing the development of  ultra-short echo time (UTE) sequences and standardized CF scoring systems, have 
greatly improved the ability of  MRI to visualize lung structure and will be essential for the conduct of  multi-
center studies (8). The use of  inhaled hyperpolarized gases (e.g., 3He, 129Xe) allows identification of  regional 
ventilation defects (i.e., a functional assessment), but it requires sophisticated gas polarizers and is generally 
limited to single breath-hold image acquisitions due to consumption of  the hyperpolarized gas. In contrast, 
fluorine-19–enhanced MRI (19F MRI), using commercially available perfluoropropane (PFP) as the inhaled 
We hypothesized that dynamic perfluorinated gas MRI would sensitively detect mild cystic 
fibrosis (CF) lung disease. This cross-sectional study enrolled 20 healthy volunteers and 24 stable 
subjects with CF, including a subgroup of subjects with normal forced expiratory volume in the first 
second (FEV1; >80% predicted, n = 9). Dynamic fluorine-19–enhanced MRI (
19F MRI) were acquired 
during sequential breath holds while breathing perfluoropropane (PFP) and during gas wash-out. 
Outcomes included the fraction of lung without significant ventilation (ventilation defect percent, 
VDP) and time constants that described PFP wash-in and wash-out kinetics. VDP values (mean 
± SD) of healthy controls (3.87% ± 2.7%) were statistically different from moderate CF subjects 
(19.5% ± 15.5%, P = 0.001) but not from mild CF subjects (10.4% ± 9.9%, P = 0.24). In contrast, the 
fractional lung volume with slow gas wash-out was elevated both in subjects with mild (9.61% ± 
4.87%; P = 0.0066) and moderate CF (16.01% ± 5.01%; P = 0.0002) when compared with healthy 
controls (3.84% ± 2.16%) and distinguished mild from moderate CF (P = 0.006). 19F MRI detected 
significant ventilation abnormalities in subjects with CF. The ability of gas wash-out kinetics to 
distinguish between healthy and mild CF lung disease subjects makes 19F MRI a potentially valuable 
method for the characterization of early lung disease in CF. This study has been registered at 
ClinicalTrials.gov (NCT03489590).
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contrast agent, does not require external gas polarization; this feature allows characterization of  regional ven-
tilation kinetics using multiple breath sequences. PFP has low blood solubility, no known anesthetic effects, 
and extremely short spin-lattice relaxation times (~18 ms), making rapid image acquisition possible. Finally, 
PFP inhalation has been shown to be safe in healthy volunteers and patients with lung disease (9–11).
In this study, we assessed the ability of  dynamic 19F MRI to characterize regional ventilation in healthy 
volunteers and subjects with CF. We hypothesized that ventilation defects would be identified by 19F MRI 
in CF subjects after multiple cycles of  PFP inhalation. We further hypothesized that characterization of  
ventilation kinetics, via calculation of  regional gas wash-in and wash-out time constants, would further 
increase the sensitivity of  this modality to detect early ventilation abnormalities.
Results
Forty-four subjects were recruited (20 healthy volunteers and 24 subjects with CF). Thirteen subjects (7 
healthy and 6 CF) were excluded from analysis due to (a) withdrawal of  consent prior to MRI (n = 1), (b) 
screen failure due to the presence of  Harrington rods (n = 1), and (c) technical issues that interfered with 
image acquisition (n = 10). Furthermore, 1 healthy male subject was excluded from analysis upon data review, 
as spirometry demonstrated an abnormal restrictive pattern and the subject was suspected to have undiag-
nosed lung disease. Figure 1 details the reasons for subject exclusion from analysis. Technical problems were 
primarily encountered early in the study and waned as the study team gained experience with study proce-
dures. Therefore, 13 healthy controls and 18 subjects with CF had full data sets available for analysis (Table 1).
Mean forced expiratory volume in the first second (FEV1) percent predicted for healthy controls was 
104.8% ± 9.6% (range 91–126), and mean FEV1 percent predicted for all CF subjects was 76.8% ± 25.9% 
(range 37–117). Nine CF subjects in a “mild CF” cohort (defined as FEV1 ≥ 80% predicted) had an average 
FEV1 of  98.2% ± 12.1%. In the remaining CF subjects, spirometry reflected moderate/severe disease sever-
ity (mean FEV1, 55.4% ± 15.9%; n = 9).
After gas exposure, no meaningful changes in mean FEV1 in either healthy control (mean change in 
FEV1, 0.5% ± 3.1%, P = 0.65) or CF subjects (mean change in FEV1, 0.89% ± 2.14%, P = 0.13) were 
observed. Oxygen saturation remained over 90% in all subjects during study procedures, and no serious 
adverse events were noted. Two subjects noted a transient decrease in voice pitch (1 control, 1 CF), which 
returned to normal within several minutes after cessation of  gas inhalation; this response was a known 
effect related to the increased density of  the gas mixture compared with room air.
Table 2 provides the absolute and fractional ventilation defect volumes in each study group. Ventilation 
defect percentage (VDP) values were significantly higher in CF subjects than healthy volunteers (14.9% ± 
12.4% vs. 3.86% ± 2.7%, P = 0.004). Although a trend of  higher VDPs in the mild CF group compared 
with healthy controls was observed, this difference was not statistically significant (10.4% ± 9.9% vs. 3.86% 
± 2.7%, P = 0.24). In sensitivity analyses, similar statistical results were obtained when using alternative 
definitions for a ventilation defect (Supplemental Tables 1 and 2; supplemental material available online 
with this article; https://doi.org/10.1172/jci.insight.133400DS1).
We next examined time constants that describe the rates of  gas wash-in (τ1) and wash-out (τ2). The 
frequency of  each time constant within the ventilated lung was plotted. Examination of  these histograms 
(Figure 2, A and B) suggested that τ2 better discriminated between study groups than τ1. Using clustering 
analysis as described in the methods, the thresholds describing abnormal τ1 and τ2 were 64.44 seconds or 
175.66 seconds for fast and slow kinetics, respectively. These were applied to quantitate the fraction of  lung 
volume (FLV) occupied by voxels with fast or slow filling (τ1) or emptying (τ2) in each subject (Figure 2, 
C–F). As shown in Figure 2 and Table 3, the FLV with slow wash-out (τ2 > 175.66 seconds) and fast wash-
out (τ2 < 64.44 seconds) discriminated between each of  the study groups, including between healthy vol-
unteers and mild CF subjects (3.8% ± 2.2% vs. 9.6% ± 4.9%, P = 0.007 for slow wash-out; 74.4% ± 12.4% 
vs. 60.9% ± 13.9%, P = 0.04 for fast wash-out). No differences were observed in either fast or slow wash-in. 
Figure 3 provides color-coded heatmaps of  τ2 values in individual subjects from each group.
As spirometry is the most commonly used measurement to assess the presence of  lung disease in 
CF, we examined the relationship between spirometric parameters (FEV1; FEF25–75) and MRI ventilation 
indices (VDP; FLV with slow τ2) (Figure 4). VDP showed significant negative correlations with FEV1 
(rho = –0.703; P = 0.001) and FEF25–75 (rho = –0.686; P = 0.0015). Similarly, strong negative correlations 
between fractional lung volume with slow τ2 and spirometric parameters were also observed (Figure 4; 
FEV1, rho = –0.686, P = 0.0015; FEF25–75, rho = –0.763, P < 0.0001).
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Discussion
This was the first study to our knowledge using inhaled PFP and 19F MRI in CF subjects. As observed in 
other populations, we did not encounter any safety concerns, and the study procedures were quite feasible. 
Some imaging sessions did not produce adequate data, which is a limitation of  this study. These failures 
primarily reflected patient claustrophobia or minor technical problems (e.g., PFP leak from face mask in 
subject with a beard) that occurred early in the study. Quality data were routinely obtained from the major-
ity of  subjects enrolled later in the study period, reflecting a learning curve with increased experience.
Other MR approaches can be used to characterize ventilation and gas exchange in the lung. Most 
commonly, hyperpolarized gases (129Xe or 3He) are used for this purpose, although availability of  these 
gases and the need for on-site polarization limit broader adoption. Furthermore, the presence of  oxygen 
reduces the available signal from hyperpolarized gases, and decaying magnetization from effects other 
than ventilation (12) complicate the ability to perform dynamic imaging. Adding to this challenge, VDP 
analysis thresholds vary among studies using hyperpolarized gas (13–15), making it difficult to compare 
VDP values across studies.
In this study, we explored the feasibility of  performing dynamic 19F MRI in stable healthy volunteers 
and CF subjects of  varying severity of  lung disease. Similar to studies with hyperpolarized gas MRI with 
single breath VDP analysis (16–19), we observed ventilation defects in CF subjects after multiple cycles 
of  PFP inhalation. These defects were most notable in the subgroup of  CF subjects with moderate/
severe disease. The numerical, but statistically nonsignificant, difference in VDP between healthy con-
trols and mild CF subjects likely relates to variability in VDP values among the mild CF group. Indeed, 5 
of  9 subjects in the mild CF group (FEV1 ≥ 80% predicted) had significantly abnormal VDPs (above the 
normal subject mean ± 1 SD value; 4 of  the 9 were above the normal subject mean ± 2 SD values), sug-
gesting greater sensitivity to disease than spirometry. Whether subjects with greater ventilation defects 
despite similar spirometry values are at greater risk for disease progression or would benefit from more 
aggressive interventions is unknown but of  interest.
The identification of  ventilation abnormalities in CF subjects is consistent with studies that used 
hyperpolarized helium, where single breath ventilation defects were detected in subjects with CF and 
preserved lung function (20). The volume of  ventilation defects detected with hyperpolarized gas MRI 
and 19F MRI are not expected to correspond directly, due to differences in signal/noise ratio, gas 
density, and gas delivery. Furthermore, because ventilation defects were identified under near-equilib-
rium conditions in this study (5 breathing cycles of  PFP wash-in), as compared with a single breath 
in hyperpolarized gas MRI studies, the obtained values cannot be directly compared. The ventilation 
Figure 1. Consort diagram detailing reasons for subject exclusion from analysis.
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defects seen in this study represent a multiple breath VDP (i.e., areas that failed to fill with gas even 
after multiple breaths of  test gas and time allotted for collateral ventilation). VDP values with each 
method may be differentially impacted by factors such as partial airways obstruction, collateral venti-
lation, or differences in tracer gas density.
In contrast to comparisons of  VDP between groups, the fractional lung ventilation with abnormal gas 
wash-out time constant values significantly discriminated between healthy volunteers and CF subjects with 
normal FEV1 values, while also discriminating between mild and moderate/severe disease severity. This 
index of  dynamic regional ventilation, therefore, appears to be more sensitive than steady-state VDP for the 
detection of  mild CF lung disease. The relative sensitivity of  these dynamic indices of  ventilation to detect 
mild disease in CF, in comparison with single breath VDP analyses by traditional hyperpolarized gas MRI, 
is unknown but a question of  interest. Similarly, the relative repeatability and feasibility of  these techniques 
should be assessed and considered in future studies.
Interestingly, in contrast to wash-out kinetics, gas wash-in kinetics were not different in CF and 
healthy subjects. The reasons for this difference are unclear. Because all subjects inhaled PFP during 
exactly 5 breathing cycles, a possibility is that we incompletely sampled the slow wash-in phase in CF 
subjects, which reduced our ability to discriminate between healthy and CF subjects. It is theoretically 
possible that, if  subjects were to continue to breathe PFP beyond the 5 cycles (i.e., reach a true plateau), 
then a slower gas wash-in tail would have been identified in CF subjects.
In order to develop a robust analytical plan for both static (VDP) and dynamic ventilation indices, we 
Table 1. Demographics of study population
Control (n = 13) Mild CF (n = 9) Moderate CF (n = 9)
Male (n) 3 5 4
Female (n) 10 4 5
Age in years (range) 27 (19–41) 27 (22–40) 33 (19–65)
Height (cm ± SD) 169.1 ± 10.4 171.3 ± 8.4 164 ± 8.8
Pre-MRI FEV1 (% pred mean ± SD)  104.8% ± 9.6%  98.2% ± 12.1%  55.4% ± 15.9% 
Pre-MRI FEV1 % pred median (range)  103 (91–126)  104 (82–117)  49 (37–75)
CFTR modulator use N/A IVA (n = 1) 
LUM/IVA (n = 3) 
TEZ/IVA (n = 1) 
No modulator (n = 4)
IVA (n = 0) 
LUM/IVA (n = 3) 
TEZ/IVA (n = 0) 
No modulator (n = 5)
Average exacerbations/year N/A 1.89 2.33
For CF patients, average exacerbations/year indicates the average number of CF exacerbations treated with oral, inhaled, or IV antibiotics over a 4-year 
time frame. LUM, lumacaftor; IVA, ivacaftor; TEZ, tezacaftor.
Table 2. 19F MRI steady state ventilation defect assessments






























3.86 (2.7) 14.9 (12.4) 10.4 (9.9)A 19.5 (13.5)B
VDP after fifth PFP inhalation cycle in healthy volunteers, all subjects with CF, and subgroups. ANOVA VDP percent = 0.002. Tukey’s HSD performed for 
multiple comparisons. AComparison between healthy and mild VDP, P = 0.24. BComparison between healthy and moderate VDP, P = 0.001. Comparison 
between mild and moderate VDP, P = 0.11.
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were challenged analytically to choose a technique to set useful thresholds that allow discrimination between 
groups. The threshold that defines a ventilation defect has been empirically defined by several methods in the 
hyperpolarized gas literature (13–15). To address this issue, we repeated our analyses using literature-defined 
thresholds and empirically defined thresholds, as well as thresholds defined using unsupervised, normal-mix-
tures clustering. Importantly, our statistical conclusions did not change, regardless of  the threshold definition 
Figure 2. Ventilation Kinetics Analysis. (A and B) Histograms of wash-in (A) and wash-out (B) time constants for healthy controls, mild CF subjects, and 
moderate CF subjects. (C–F) Scatter and box plots (median ± 95% CI) demonstrating FLV of fast wash-in (C), fast wash-out (D), slow wash-in (E), and slow 
washout (F). ANOVA. Tukey’s honest significance test (HSD) was performed for multiple between-group comparisons. Slow emptying fraction: healthy vs. 
mild CF, P = 0.007; mild CF vs. mod CF, P = 0.006. Fast emptying fraction: healthy vs. mild CF, P = 0.04; mild vs. moderate CF, P = 0.13).
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that was used. Ultimately, we chose to report the values for VDP defined as voxels under 10% of the individu-
al’s maximal signal intensity, recognizing that this may serve as a guideline to future investigators.
We took a similar approach to identifying the thresholds that defined τ1 and τ2 values that discriminated 
between groups. Whether thresholds were defined by visual inspection of  data histograms or through use 
of  normal mixtures clustering analyses, similar conclusions were reached. Although the FLV with slow and 
fast τ2 values differentiated between normal and mild CF subjects, it is possible that even greater discrimina-
tion between health and mild CF disease can be achieved by exploring other PFP inhalation patterns that 
were not tested in this study. One important limitation of  this study is the absence of  test-retest variability 
data. Although data in asthma suggest acceptable short-term repeatability (21), this is a critical step in the 
development of  19F MRI for CF. Reassuringly, repeatability studies with hyperpolarized gas MRI in CF do 
suggest that ventilation defects are quite stable (19), lowering the chance the intrinsic biological variability 
will be limiting. Future studies will address these concerns.
In conclusion, we demonstrated the capability of  dynamic 19F MRI to detect ventilation defects and to 
visualize slow emptying compartments in subjects with mild CF lung disease. These findings suggest that 
dynamic assessment of  PFP gas wash-out with 19F MRI is more sensitive to disease than spirometry. After 
adapting this technology for use in pediatric patients and incorporating emerging MR assessments of  lung 
structure (e.g., UTE 1H-MRI), this MR technology may provide a safer and more comprehensive means 
of  characterizing early lung disease. As new therapies are developed for CF patients with increasingly mild 
disease, these techniques could have a profound impact on our ability to assess treatment responses in this 
population. The combination of  these capabilities is likely to make 19F MRI superior to other lung-imaging 
modalities. 19F MRI presents an ionizing radiation–free method of  quantitatively measuring lung function 
in both healthy and diseased populations, offering an alternative outcome measure for CF clinical trials.
Methods
Subject demographics are shown in Table 1. Twenty healthy volunteers (mean age 27 years) and 24 subjects 
with stable CF (mean age 30 years) were recruited between November 2014 and April 2018. Healthy vol-
unteers were nonsmokers with normal spirometry and no contraindications to MRI. CF subject exclusion 
criteria included FEV1 under 35%, active smoking, coexistent asthma, recent pulmonary exacerbation, a 
contraindication to MRI, or investigational drug use. A subcohort of  CF subjects with preserved lung func-
tion (FEV1 > 80% predicted) was specifically targeted for inclusion.
Spirometry. Spirometry was performed using a KoKo spirometer (NSpire Health) according to Ameri-
can Thoracic Society guidelines (22).
MRI procedures. 1H-MRI GRE VIBE images were acquired during a 15-second breath hold, followed by 
19F MRI with inhaled PFP as the gaseous contrast agent (79% PFP; 21% O2, premixed medical grade gas; 
Air Liquide Healthcare). Scans were performed on a Siemens Prisma 3.0 Tesla MRI system (Siemens Med-
ical Systems) with a commercially available 8-channel 19F-tuned chest coil (ScanMed Inc.). MR parameters 
Table 3. Kinetics of 19F MRI ventilation wash-in/wash-out


















































Statistical gas kinetic results. Fractional lung volume (FLV) represents the percentage of lung with fast and slow wash-in and wash-out time constants. 
AP value via ANOVA < 0.0001 for FLV with fast and slow τ2. Tukey’s HSD performed for multiple comparisons. 
BComparison between healthy and mild FLV 
with fast τ2, P = 0.04. 
CComparison between healthy and moderate FLV with fast τ2, P < 0.0002. Comparison between mild and moderate FLV with fast τ2, 
P = 0.13. DComparison between healthy and mild FLV with slow τ2, P = 0.007. 
EComparison between healthy and moderate FLV with fast τ2, P < 0.00001. 
Comparison between mild and moderate FLV with fast τ2, P = 0.006.
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for proton images were as follows, using Siemens GRE: TE, 3.34 ms; TR, 108 ms; flip angle, 25; resolution, 
3.125 mm × 3.125 mm × 15 mm. MR parameters for the 19F images were as follows, using SIEMENS 3D 
VIBE: repetition time (TR), 13 ms; echo time (TE), 1.61 ms; averages, 2; flip angle (FA), 70; resolution, 
6.25 mm × 6.25 mm; slice thickness, 15 mm; number of  slices, 18.
A gas-delivery system using a mask/non-rebreathing circuit was manufactured based on prior work by 
Halaweish and colleagues (11, 23) and delivered PFP or room air during scans. Ventilation was monitored 
and coached using a pneumotachometer, and gas-empty bag sensors automatically triggered a switch to 
room air if  the PFP source was depleted during the study.
During gas wash-in cycles, subjects took 1 tidal breath of  PFP, exhaled via a 1-way valve, and then 
inhaled PFP for a deep inspiration and 12-second breath hold while images were obtained. Five imaging 
cycles were performed without breaks during PFP inhalation (wash-in, lasting approximately 2 minutes). 
After switching to room air, an identical breathing pattern and imaging was performed to characterize 
PFP wash-out. A minimum of  5 wash-out imaging cycles were performed, with additional room air cycles 
repeated if  residual PFP signal was visible.
Safety assessments. Pulse oximetry, exhaled CO2, and heart rate were monitored during the MRI procedure. 
These signals were digitized and recorded through a pair of  digitizing acquisition modules (Windaq, Model 
DI-149, DataQ Instruments). Spirometry was performed before and after gas inhalation/MRI sequences.
Image processing. MRI processing was performed via semiautomated in-house scripts using MATLAB 
(Mathworks Inc.), 3D Slicer (http://www.slicer.org, v4.8.1), and custom Python software (Python Soft-
ware Foundation; available upon request via Material Transfer Agreement). A near steady state image was 
defined as the fifth wash-in image from the 4D functional 19F data set (Figure 5 and Supplemental Videos 
1–3). Lung boundaries and regions of  interest were defined using the steady state image and the proton 
scan using 3D Slicer, using both semiautomated region growing and manual visual registration. Maximal 
signal intensity for each subject was defined as the 95th percentile of  that individual subject’s intensity dis-
Figure 3. Representative color-coded heatmaps of τ2, demonstrating distribution of voxels with prolonged gas wash-
out. The x and y axes are marked in centimeters. (A) Healthy control. (B) Mild CF. (C) Moderate CF.
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tribution to exclude outlying voxels. After noise correction by subtracting mean background signal, VDP 
was defined as voxels not meeting a threshold of  over 10% of  the maximal signal intensity.
To evaluate regional dynamic ventilation, PFP signals were analyzed in the time domain for all venti-
lated voxels with custom Python software. The signal-time curve for each voxel was fitted with an exponen-
tial model to estimate the time constants that characterized the kinetics of  gas wash-in (τ1) and wash-out 
(τ2), based on a previously described ventilation model (24).
This study has been registered at ClinicalTrials.gov(NCT03489590).
Statistics. Statistical analyses were performed using JMP Pro 14 and SigmaPlot. Changes in FEV1 per-
centage predicted before and after gas exposure were analyzed with paired, 2-tailed t tests for healthy and 
CF subjects separately. The frequency of  each time constant in the whole ventilated lung was calculated 
and displayed via histograms and τ maps. Normal mixture clustering was performed on all τ1 and τ2 values 
in all subjects, specifying a 3-cluster analysis (fast, regular, and slow). Two thresholds for each parameter 
were defined based on the resulting cluster edges, describing abnormal τ1 and τ2. These thresholds were 
confirmed by visual inspection of  the histograms, and a sensitivity analysis showing that selection of  other 
thresholds did not alter the conclusions is presented in Supplemental Tables 1 and 2. Percentage of  lung 
volume occupied by voxels above and below clustering-defined thresholds were compared between healthy, 
mild CF, and moderate CF groups with 1-way ANOVA, followed by group comparisons corrected with 
Tukey’s method for multiple comparisons. Correlations between fractional lung volumes and spirometry 
measurements were performed using Spearman rank order correlation. All tests were 2 sided, and P values 
less than 0.05 were considered significant.
Figure 4. Correlations of VDP and FLV with FEV1. Scatterplot demonstrating the correlation (via Spearman rank-order correlation) of VDP with FEV1 (A) and 
FEF25–75 (B) in CF subjects. (A) FEV1 correlation coefficient, –0.703; P = 0.001. (B) FEF25–75 correlation coefficient, –0.686; P = 0.0015. C and D demonstrate correlation 
of FLV with slow τ2 with FEV1 and FEF25–75, respectively. (C) FEV1 correlation coefficient, –0.686; P = 0.0015. (D) FEF25–75 correlation coefficient, –0.763; P < 0.0001.
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Study approval. This study was conducted in accordance with the amended Declaration of  Helsinki. 
The University of  North Carolina IRB approved the study, and written informed consent was obtained 
from all participants.
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Figure 5. Example 4D 19F image set for a healthy control, mild CF subject, and moderate CF subject with lung contours. All image sets are 3D so acqui-
sition over time results in a 4D data set. Steady state image for VDP calculation is defined as the fifth wash-in image. Images in sequence: 1H GRE, first 
wash-in, fifth wash-in, first wash-out, final wash-out. Signal/noise ratio (SNR) for first wash-in in mild CF subject was 8.342 ± 3.078, compared with SNR 
of 15.562 ± 4.073 for fifth wash-in image.
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